Akero Therapeutics claimed a win in severe MASH on Monday morning, as the company’s candidate efruxifermin showed a 24% ...

Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...

KEY TAKEAWAYS: 70% of Sponsors miss their milestones by an average of eight months, suggesting the clinical trial recruitment ...

A London-based biotech has emerged from stealth with a personalized T cell therapy platform that it says could create ...

Eisai and Biogen scored an approval for once-monthly IV maintenance dosing of their Alzheimer’s drug Leqembi, as part of what ...

Five months after the FDA blocked its plans for accelerated approval, Agenus is moving ahead with discussions with potential ...

Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...

President Donald Trump's communications pause for HHS, FDA and other health-related agencies could push some drug approval ...

Merck's Keytruda and Eisai's Lenvima combo with chemo failed survival endpoint in gastroesophageal cancer study, but ...

Aardvark Therapeutics files for IPO. Company develops hunger-targeting obesity drug ARD-101 and ARD-201, led by CEO Tien Lee.

Moderna’s chief information officer Brad Miller is 'retiring' in February, a company spokesperson confirmed to Endpoints News ...

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive ...